Liminal BioSciences Inc (LMNL) stock is up 18.74% over the past week and gets a Bullish rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.
InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.
Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .
What's Happening With LMNL Stock Today?
Liminal BioSciences Inc (LMNL) stock is trading at $5.45 as of 1:19 PM on Monday, Feb 8, a rise of $0.23, or 4.31% from the previous closing price of $5.22. The stock has traded between $5.29 and $5.81 so far today. Volume today is 1,620,333 compared to average volume of 1,357,128.
To see InvestorsObserver's Sentiment Score for Liminal BioSciences Inc click here.
More About Liminal BioSciences Inc
Liminal Biosciences engages in clinical-stage research and commercialization of fibrosis treatments. The company operates in two segments: small molecule therapeutics and plasma-derived therapeutics. The small molecule segment develops and commercializes treatments for lung, liver, and kidney conditions. The plasma-derived segment sells proteins and specialty plasma in addition to developing a plasma treatment product. Liminal Biosciences does business in Canada, the U.K., and the U.S., and nearly all of its revenue comes from the plasma-derived therapeutics segment.
Click Here to get the full Stock Score Report on Liminal BioSciences Inc (LMNL) Stock.
